Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for zofenopril, the scientific conclusions are as follows:

In view of available data on palpitations, hypotension, syncope, pruritus, urticaria and hyperkalaemia from spontaneous reports, including in some cases a positive de-challenge, and in view of a plausible mechanism of action, the PRAC considers a causal relationship between zofenopril and palpitations, hypotension, syncope, pruritus, urticaria and hyperkalaemia is at least a reasonable possibility. The PRAC concluded that the product information of products containing zofenopril should be amended accordingly.

Having reviewed the PRAC recommendation, the CMDh agrees with the PRAC overall conclusions and grounds for recommendation.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for zofenopril the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing zofenopril is unchanged subject to the proposed changes to the product information

The CMDh recommends that the terms of the marketing authorisation(s) should be varied.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text **underlined and in bold**, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.8

The following adverse reactions should be added with a frequency Rare:

SOC **Cardiac disorders**
Palpitations

SOC **Vascular disorders**
Hypotension (see section 4.4), syncope

SOC Skin and subcutaneous tissue disorders
Pruritus, urticaria

SOC **Metabolism and nutrition disorders**
Hyperkalaemia (see section 4.4, 4.5)

Package Leaflet

Rare side effects (may affect up to 1 in 1,000 people):

- **fainting (syncope)**
- **a forceful heartbeat that may be rapid or irregular (palpitations)**
- **low blood pressure**
- **hives (urticaria)**
- **itching**
- **increased levels of potassium in your blood**

Following the table of ADRs in section 4.8 of the SmPC, any reference to the above undesirable effects as adverse reactions associated with ACE inhibitors therapy in general should be deleted.

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	September 2024 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	3 November 2024
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	2 January 2025